NEW YORK, Dec. 14 /PRNewswire/ -- Pfizer Inc said today that the U.S. District Court for the Southern District of New York has denied a motion for a preliminary injunction that would have blocked further sales of its inhalable insulin medication, Exubera(R), in the U.S. The preliminary injunction was requested by Novo Nordisk as part of a patent infringement case that will be heard by the same court. Exubera is the only inhalable form of insulin to be approved by the FDA. The court's decision allows the product to remain on the U.S. market, and available to patients, while the case proceeds to trial. DATASOURCE: Pfizer Inc CONTACT: Bryant Haskins, +1-212-733-8719 Web site: http://www.pfizer.com/ Company News On-Call: http://www.prnewswire.com/comp/688250.html Company News On-Call: Pfizer's press releases are available through PR Newswire's Company News On-Call service on PRN's Web Site. Visit http://www.prnewswire.com/comp/688250.html

Copyright